tbuckley/cabot-search huggingface dataset:
Evidence is insufficient to back mandatory NHS staff vaccination, says House of Lords committee
Authors: Zosia Kmietowicz
Journal: BMJ (2021)

Evidence is insufficient to back mandatory NHS staff vaccination, says House of Lords committee Zosia KmietowiczA House of Lords committee has raised several concerns about the proposed legislation to make vaccination against SARS-CoV-2 mandatory for all NHS staff in England, particularly whether the benefits of vaccinating the remaining 8% of NHS workers were proportionate and how the NHS would cope with losing the 5.4% who don't want to be vaccinated.
Error in Affiliation
Journal: JAMA Network Open (2021)

Luca Bastiani, PhD; Fabio Paolicchi, RT; Lorenzo Faggioni, MD, PhD; Massimo Martinelli, PhD; Roberta Gerasia, RT; Chiara Martini, RT; Patrizia Cornacchione, RT; Matteo Ceccarelli, MP; Dante Chiappino, MD; Daniele Della Latta, BSc; Jacopo Negri, RT; Donatella Pertoldi, RT; Donato Negro, RT, MSc; Giovanni Nuzzi, RT; Vincenzo Rizzo, RT; Paola Tamburrino, RT; Chiara Pozzessere, MD; Giacomo Aringhieri, MD, PhD; Davide Caramella, MD
Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis
Authors: Adithya Cattamanchi, Tania F. Reza, Talemwa Nalugwa, Katherine Adams, Mariam Nantale, Denis Oyuku, Sarah Nabwire, Diana Babirye, Stavia Turyahabwe, Austin Tucker, Hojoon Sohn, Olivia Ferguson, Ryan Thompson, Priya B. Shete, Margaret A. Handley, Sara Ackerman, Moses Joloba, David A.J. Moore, J. Lucian Davis, David W. Dowdy, Katherine Fielding, Achilles Katamba
Journal: New England Journal of Medicine (2021)

Effective strategies are needed to facilitate the prompt diagnosis and treatment of tuberculosis in countries with a high burden of the disease.We conducted a cluster-randomized trial in which Ugandan community health centers were assigned to a multicomponent diagnostic strategy (on-site molecular testing for tuberculosis, guided restructuring of clinic workflows, and monthly feedback of quality metrics) or routine care (on-site sputum-smear microscopy and referral-based molecular testing). The primary outcome was the number of adults treated for confirmed tuberculosis within 14 days after presenting to the health center for evaluation during the 16-month intervention period. Secondary outcomes included completion of tuberculosis testing, same-day diagnosis, and same-day treatment. Outcomes were also assessed on the basis of proportions.A total of 20 health centers underwent randomization, with 10 assigned to each group. Of 10,644 eligible adults (median age, 40 years) whose data were evaluated, 60.1% were women and 43.8% had human immunodeficiency virus infection. The intervention strategy led to a greater number of patients being treated for confirmed tuberculosis within 14 days after presentation (342 patients across 10 intervention health centers vs. 220 across 10 control health centers; adjusted rate ratio, 1.56; 95% confidence interval [CI], 1.21 to 2.01). More patients at intervention centers than at control centers completed tuberculosis testing (adjusted rate ratio, 1.85; 95% CI, 1.21 to 2.82), received a same-day diagnosis (adjusted rate ratio, 1.89; 95% CI, 1.39 to 2.56), and received same-day treatment for confirmed tuberculosis (adjusted rate ratio, 2.38; 95% CI, 1.57 to 3.61). Among 706 patients with confirmed tuberculosis, a higher proportion in the intervention group than in the control group were treated on the same day (adjusted rate ratio, 2.29; 95% CI, 1.23 to 4.25) or within 14 days after presentation (adjusted rate ratio, 1.22; 95% CI, 1.06 to 1.40).A multicomponent diagnostic strategy that included on-site molecular testing plus implementation supports to address barriers to delivery of high-quality tuberculosis evaluation services led to greater numbers of patients being tested, receiving a diagnosis, and being treated for confirmed tuberculosis. (Funded by the National Heart, Lung, and Blood Institute; XPEL-TB ClinicalTrials.gov number, NCT03044158.).
FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape
Authors: Lei Wu, Yanquan Xu, Huakan Zhao, Yu Zhou, Yu Chen, Shuai Yang, Juan Lei, Jiangang Zhang, Jingchun Wang, Yongzhong Wu, Yongsheng Li
Journal: Theranostics (2021)

Background: FcγRIIB, the sole inhibitory receptor of the Fc gamma receptor family, plays pivotal roles in innate and adaptive immune responses. However, the expression and function of FcγRIIB in myeloid-derived suppressor cells (MDSCs) remains unknown. This study aimed to investigate whether and how FcγRIIB regulates the immunosuppressive activity of MDSCs during cancer development. Methods: The MC38 and B16-F10 tumor-bearing mouse models were established to investigate the role of FcγRIIB during tumor progression. FcγRIIB-deficient mice, adoptive cell transfer, mRNA-sequencing and flow cytometry analysis were used to assess the role of FcγRIIB on immunosuppressive activity and differentiation of MDSCs. Results: Here we show that FcγRIIB was upregulated in tumor-infiltrated MDSCs. FcγRIIB-deficient mice showed decreased accumulation of MDSCs in the tumor microenvironment (TME) compared with wild-type mice. FcγRIIB was required for the differentiation and immunosuppressive activity of MDSCs. Mechanistically, tumor cell-derived granulocyte-macrophage colony stimulating factor (GM-CSF) increased the expression of FcγRIIB on hematopoietic progenitor cells (HPCs) by activating specificity protein 1 (Sp1), subsequently FcγRIIB promoted the generation of MDSCs from HPCs via Stat3 signaling. Furthermore, blockade of Sp1 dampened MDSC differentiation and infiltration in the TME and enhanced the anti-tumor therapeutic efficacy of gemcitabine. Conclusion: These results uncover an unrecognized regulatory role of the FcγRIIB in abnormal differentiation of MDSCs during cancer development and suggest a potential therapeutic target for anti-tumor therapy.
Molecular analysis of TCGA breast cancer histologic types
Authors: Aatish Thennavan, Francisco Beca, Youli Xia, Susana Garcia-Recio, Kimberly Allison, Laura C. Collins, Gary M. Tse, Yunn-Yi Chen, Stuart J. Schnitt, Katherine A. Hoadley, Andrew Beck, Charles M. Perou
Journal: Cell Genomics (2021)

Breast cancer is classified into multiple distinct histologic types, and many of the rarer types have limited characterization. Here, we extend The Cancer Genome Atlas Breast Cancer (TCGA-BRCA) dataset with additional histologic type annotations, in a total of 1063 breast cancers. We analyze this extended dataset to define transcriptomic and genomic profiles of six rare special histologic types: cribriform, micropapillary, mucinous, papillary, metaplastic, and invasive carcinoma with medullary pattern. We show the broader applicability of our constructed special histologic type gene signatures in the TCGA Pan-Cancer Atlas dataset with a predictive model that detects mucinous histologic type across cancers of other organ systems. Using a normal mammary cell differentiation score analysis, we order histologic types into a continuum from stem cell-like to luminal progenitor-like to mature luminal-like. Finally, we classify TCGA-BRCA into 12 consensus groups based on integrated genomic and histological features. We present a rich openly accessible resource of histologic and genomic characterization of TCGA-BRCA to enable studies of the range of breast cancers.
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis
Authors: Colin Baigent, Stephan Windecker, Daniele Andreini, Elena Arbelo, Emanuele Barbato, Antonio L Bartorelli, Andreas Baumbach, Elijah R Behr, Sergio Berti, Héctor Bueno, Davide Capodanno, Riccardo Cappato, Alaide Chieffo, Jean-Philippe Collet, Thomas Cuisset, Giovanni de Simone, Victoria Delgado, Paul Dendale, Dariusz Dudek, Thor Edvardsen, Arif Elvan, José R González-Juanatey, Mauro Gori, Diederick Grobbee, Tomasz J Guzik, Sigrun Halvorsen, Michael Haude, Hein Heidbuchel, Gerhard Hindricks, Borja Ibanez, Nicole Karam, Hugo Katus, Fredrikus A Klok, Stavros V Konstantinides, Ulf Landmesser, Christophe Leclercq, Sergio Leonardi, Maddalena Lettino, Giancarlo Marenzi, Josepa Mauri, Marco Metra, Nuccia Morici, Christian Mueller, Anna Sonia Petronio, Marija M Polovina, Tatjana Potpara, Fabien Praz, Bernard Prendergast, Eva Prescott, Susanna Price, Piotr Pruszczyk, Oriol Rodríguez-Leor, Marco Roffi, Rafael Romaguera, Stephan Rosenkranz, Andrea Sarkozy, Martijn Scherrenberg, Petar Seferovic, Michele Senni, Francesco R Spera, Giulio Stefanini, Holger Thiele, Daniela Tomasoni, Luccia Torracca, Rhian M Touyz, Arthur A Wilde, Bryan Williams
Journal: Cardiovascular Research (2021)

Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Hsa_circ_0004287 inhibits macrophage-mediated inflammation in an N6-methyladenosine–dependent manner in atopic dermatitis and psoriasis
Authors: Lan Yang, Jinrong Fu, Xiao Han, Caiyan Zhang, Li Xia, Ronghui Zhu, Saihua Huang, Wenfeng Xiao, Hongmiao Yu, Yajing Gao, Qiuyan Liang, Wei Li, Yufeng Zhou
Journal: Journal of Allergy and Clinical Immunology (2021)
Cover Image, Volume 41, Issue 12
Authors: Ya Wang, Long Qiao, Jie Yang, Xiong Li, Yaqi Duan, Jiahao Liu, Shaoqi Chen, Huayi Li, Dan Liu, Tian Fang, Jingjing Ma, Xiaoting Li, Fei Ye, Junxiang Wan, Juncheng Wei, Qin Xu, Ensong Guo, Ping Jin, Mingfu Wu, Lin Zhang, Yun Xia, Yaqun Wu, Jun Shao, Yaojun Feng, Qing Zhang, Zongyuan Yang, Gang Chen, Qinghua Zhang, Xingrui Li, Shixuan Wang, Junbo Hu, Xiaoyun Wang, Mona P. Tan, Kazuaki Takabe, Beihua Kong, Qifeng Yang, Ding Ma, Qinglei Gao
Journal: Cancer Communications (2021)

The cover image is based on the Original Article Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study by Qinglei Gao et al., https://doi.org/10.1002/cac2.12233.
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
Authors: Timothy A. Bates, Savannah K. McBride, Bradie Winders, Devin Schoen, Lydie Trautmann, Marcel E. Curlin, Fikadu G. Tafesse
Journal: JAMA (2021)

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research
Authors: J. Ma, J. Zhang, Y. Yang, D. Zheng, X. Wang, H. Liang, L. Zhang, Y. Xin, X. Ling, C. Fang, H. Jiang, H. Meng, W. Zheng
Journal: Annals of Oncology (2021)
Error in Figure 2 and Figure 3
Journal: JAMA Network Open (2021)

Brett D. M. Jones, MD, MSc; Lais B. Razza, BSc; Cory R. Weissman, MD; Jewel Karbi, MD; Tya Vine, HBSc; Louise S. Mulsant, BASc; Andre R. Brunoni, MD, PhD; M. Ishrat Husain, MBBS, MD; Benoit H. Mulsant, MD, MSc; Daniel M. Blumberger, MD, MSc; Zafiris J. Daskalakis, MD, PhD
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target
Authors: Paulina Valadez-Cosmes, Sofia Raftopoulou, Zala Nikita Mihalic, Gunther Marsche, Julia Kargl
Journal: Pharmacology & Therapeutics (2021)

Myeloperoxidase is a heme-peroxidase which makes up approximately 5% of the total dry cell weight of neutrophils where it is predominantly found in the primary (azurophilic) granules. Other cell types, such as monocytes and certain macrophage subpopulations also contain myeloperoxidase, but to a much lesser extent. Initially, the function of myeloperoxidase had been mainly associated with its ability as a catalyzer of reactive oxidants that help to clear pathogens. However, over the past years non-canonical functions of myeloperoxidase have been described both in health and disease. Attention has been specially focused on inflammatory diseases, in which an exacerbate infiltration of leukocytes can favor a poorly-controlled production and release of myeloperoxidase and its oxidants. There is compelling evidence that myeloperoxidase derived oxidants contribute to tissue damage and the development and propagation of acute and chronic vascular inflammation. Recently, neutrophils have attracted much attention within the large diversity of innate immune cells that are part of the tumor microenvironment. In particular, neutrophil-derived myeloperoxidase may play an important role in cancer development and progression. This review article aims to provide a comprehensive overview of the roles of myeloperoxidase in the development and progression of cancer. We propose future research approaches and explore prospects of inhibiting myeloperoxidase as a strategy to fight against cancer.
LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial
Authors: X. Shang, C. Zhang, G. Zhao, W. Zhang, L. Liu, X. Duan, J. Yue, Z. Ma, C. Chen, B. Meng, X. Ren, H. Jiang
Journal: Annals of Oncology (2021)
Benchmarking UMI-based single-cell RNA-seq preprocessing workflows
Authors: Yue You, Luyi Tian, Shian Su, Xueyi Dong, Jafar S. Jabbari, Peter F. Hickey, Matthew E. Ritchie
Journal: Genome biology (2021)

Abstract Background Single-cell RNA-sequencing (scRNA-seq) technologies and associated analysis methods have rapidly developed in recent years. This includes preprocessing methods, which assign sequencing reads to genes to create count matrices for downstream analysis. While several packaged preprocessing workflows have been developed to provide users with convenient tools for handling this process, how they compare to one another and how they influence downstream analysis have not been well studied. Results Here, we systematically benchmark the performance of 10 end-to-end preprocessing workflows ( Cell Ranger , Optimus , salmon alevin , alevin-fry , kallisto bustools , dropSeqPipe , scPipe , zUMIs , celseq2 , and scruff ) using datasets yielding different biological complexity levels generated by CEL-Seq2 and 10x Chromium platforms. We compare these workflows in terms of their quantification properties directly and their impact on normalization and clustering by evaluating the performance of different method combinations. While the scRNA-seq preprocessing workflows compared vary in their detection and quantification of genes across datasets, after downstream analysis with performant normalization and clustering methods, almost all combinations produce clustering results that agree well with the known cell type labels that provided the ground truth in our analysis. Conclusions In summary, the choice of preprocessing method was found to be less important than other steps in the scRNA-seq analysis process. Our study comprehensively compares common scRNA-seq preprocessing workflows and summarizes their characteristics to guide workflow users.
Tobacco-free Nicotine — New Name, Same Scheme?
Authors: Sam N. Cwalina, Rob McConnell, Neal L. Benowitz, Jessica L. Barrington-Trimis
Journal: New England Journal of Medicine (2021)

E-cigarettes that claim to contain "tobacco-free" synthetic nicotine — nicotine that isn't derived from tobacco — are proliferating. Such products may threaten ongoing public health efforts to reduce e-cigarette use among adolescents and young adults.
Adverse Outcomes With Early Venous Thromboembolism Prophylaxis in Neurosurgical Trauma Patients—Are We Crossing the Blood-Brain Barrier?
Authors: Purvi P. Patel, Patrick M. McCarthy, Matthew J. Martin
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
Authors: Evangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, Chara Giatra, John V. Asimakopoulos, Maria Dimou, Aimilia D. Sklirou, Ioannis Ntanasis-Stathopoulos, Ismini Darmani, Alexandros Briasoulis, Efstathios Kastritis, Maria K. Angelopoulou, Ioannis Baltadakis, Panayiotis Panayiotidis, Ioannis P. Trougakos, Theodoros P. Vassilakopoulos, Maria Pagoni, Meletios A. Dimopoulos
Journal: Blood (2021)
Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma
Authors: Zachary Jackson, Changjin Hong, Robert Schauner, Boro Dropulic, Paolo F. Caimi, Marcos J.G. de Lima, Kalpana Gupta, Jane Reese, Tae Hyun Hwang, David Wald
Journal: Blood (2021)
Errors in Results Section
Authors: Patrick Mccleskey, Amara Lieberman, Lisa Herrinton
Journal: JAMA Dermatology (2021)

Andrew Blauvelt, MD, MBA; Henrique D. Teixeira, PhD, MBA; Eric L. Simpson, MD, MCR; Antonio Costanzo, MD; Marjolein De Bruin-Weller, MD; Sebastien Barbarot, MD, PhD; Vimal H. Prajapati, MD; Peter Lio, MD; Xiaofei Hu, PhD; Tianshuang Wu, PhD; John Liu, MD, MS; Barry Ladizinski, MD, MPH, MBA; Alvina D. Chu, MD; Kilian Eyerich, MD
Real models: The limits of behavioural evidence for understanding the ANS
Authors: Denitza Dramkin, Darko Odic
Journal: Behavioral and Brain Sciences (2021)

Abstract Clarke and Beck use behavioural evidence to argue that (1) approximate ratio computations are sufficient for claiming that the approximate number system (ANS) represents the rationals , and (2) the ANS does not represent the reals . We argue that pure behaviour is a poor litmus test for this problem, and that we should trust the psychophysical models that place ANS representations within the reals.
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
Authors: G. Mazzaschi, G. Milanese, L. Moron Dalla Tor, L. Leo, M. Balbi, F. Trentini, M. Manini, C. Pavone, M. Silva, R.E. Ledda, R. Minari, P. Bordi, S. Buti, A. Leonetti, G. Roti, F. Quaini, N. Sverzellati, M. Tiseo
Journal: Annals of Oncology (2021)
Abstract 9502: Prehospital Variables Associated With Neurologically Intact Survival in Elderly Survivors After Out-of-Hospital Cardiac Arrest: Evidence from a Japanese Nationwide Population-based Cohort Study
Authors: Akira Funada, Yoshikazu Goto, Masayuki Takamura
Journal: Circulation (2021)

Introduction: Prehospital variables associated with neurologically intact survival in elderly survivors after out-of-hospital cardiac arrest (OHCA) are unclear and could differ according to age. Methods: We evaluated 6,349 elderly patients with OHCA (age ≥ 65 years) of cardiac origin who achieved prehospital return of spontaneous circulation (ROSC) and survived for at least 1-month after OHCA. Data were obtained from the prospectively recorded All-Japan Utstein Registry between 2011 and 2016. Patients witnessed by emergency medical service providers were excluded. The primary outcome was 1-month neurologically intact survival, defined as a cerebral performance category (CPC) score of 1-2. Patients were divided into three groups by age (65-74, 75-89, or ≥ 90 years). The time from call receipt to ROSC was calculated. Results: The rates of 1-month CPC 1-2 in patients aged 65-74, 75-89, and ≥ 90 years were 66.5% (2,079/3,125), 52.9% (1,557/2,943), and 42.7% (120/281), respectively (p for trend &lt; 0.001). In multivariate logistic regression analysis, initial shockable rhythm and witnessed arrest were significantly associated with 1-month CPC 1-2 for all age groups (Table). However, the presence of bystander cardiopulmonary resuscitation (CPR) was significantly associated with 1-month CPC 1-2 only for patients aged 65-74 years. Time from call receipt to ROSC was not associated with 1-month CPC 1-2 for patients aged ≥ 90 years. In recursive partitioning analysis, the best single predictor for 1-month CPC 1-2 was initial shockable rhythm for all age groups. The next predictor for patients aged 65-74 years with initial shockable rhythm was the presence of bystander CPR, whereas the witnessed arrest was the next predictor for patients aged 65-74 years with initial non-shockable rhythm and other age groups regardless of the initial rhythm. Conclusions: Prehospital variables associated with neurologically intact survival in elderly survivors after OHCA varied with age.
Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
Authors: Janine Stutterheim, Paola De Lorenzo, Inge M. Van Der Sluis, Julia Alten, Philip Ancliffe, Andishe Attarbaschi, Luis Alberto Aversa, Judith M. Boer, Andrea Biondi, Benoit Brethon, Paulina Diaz, Giovanni Gazzaniga, Gabriele Escherich, Alina Ferster, Rishi S Kotecha, Birgitte Lausen, Alex WK Leung, Franco Locatelli, Lewis B. Silverman, Jan Stary, Tomasz Szczepanski, Vincent H.J. Van Der Velden, Ajay Vora, Jan Zuna, Martin Schrappe, Maria Grazia Valsecchi, Rob Pieters
Journal: Blood (2021)